Apr 07,2022

Insulet to Announce First Quarter 2022 Financial Results on May 5, 2022

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company) today announced plans to release its financial results for the first quarter of 2022 on May 5, 2022 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).

View Analyst & Ambassador Comments
Go to original news
Apr 07,2022

Analysts see Medtronic’s diabetes, spine businesses as most likely spinoff candidates

Needham analysts published a report singling out the diabetes and spine businesses as possible spinoff options for Medtronic.

View Analyst & Ambassador Comments
Go to original news
Apr 07,2022

DiabetesWise launches platform for provider decision-making on diabetes devices

DiabetesWise announced that it launched its DiabetesWise Pro website to help providers make informed decisions on diabetes devices. DiabetesWise says it designed the website as an easy-to-use and free tool for providers to access in the clinical practice or at the point of care. They can identify the best available diabetes device on the market for their patients, followed by the necessary steps for ordering the device based on insurance type.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Apr 08,2022

The Worldwide Diabetes Devices Industry is Expected to Reach $42+ Billion by 2027

The Global Diabetes Devices Market size was estimated at USD 27.75 billion in 2021 and expected to reach USD 29.79 billion in 2022, and is projected to grow at a CAGR 7.52% to reach USD 42.89 billion by 2027.

View Analyst & Ambassador Comments
Go to original news
Apr 08,2022

Design of the DAVOS Study: Diabetes Smartphone App, a Fully Automatic Transmission of Data From the Blood Glucose Meter and Insulin Pens Using Wireless Technology to Enhance Diabetes Self-Management—A Study Protocol for a Randomized Controlled Trial

The aim of this study is to evaluate the outcome of diabetes treatment assisted by a digital health application compared with standard diabetes therapy.

CLINICAL STUDY

#mobile app

#bgm

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Apr 11,2022

Tandem Diabetes Care to Announce First Quarter 2022 Financial Results on May 4, 2022

The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2022 financial and operating results.

View Analyst & Ambassador Comments
Go to original news
Apr 11,2022

Diabetes Specialists Value CGM Despite Challenges in Prescribing and Data Review Process

Diabetes clinicians are key facilitators of continuous glucose monitoring (CGM) provision, but data on provider behavior related to CGM use and CGM generated data are limited.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 12,2022

Vida Health Founder and CEO Stephanie Tilenius to Participate at William Blair Healthcare Innovators Conference

Vida Health, a leader in virtual whole health chronic care, today announced that its founder and CEO Stephanie Tilenius will be participating at William Blair Healthcare Innovators Conference on Tuesday, April 12, 2022.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Apr 12,2022

Glycemic Outcomes During Real-World Hybrid Closed-Loop System Use by Individuals With Type 1 Diabetes in the United States

Glycemic outcomes during real-world hybrid closed-loop (HCL) system use by individuals with type 1 diabetes, in the United States, were retrospectively analyzed.

CLINICAL STUDY

#closed loop

View Analyst & Ambassador Comments
Go to original news
Apr 12,2022

Diabetes tech startup Ryse Health raises $3.4M

Ryse Health, a startup providing care offerings to diabetes patients, announced today that it raised $3.4 million in seed funding. The company, which has offices in Baltimore and Arlington, Virginia, provides tech-enabled, office-based and virtual care to type 2 diabetes patients.

FUNDING SEED ROUND
View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES